Immunophenotypic and genetic features of common B-cell neoplasms
| Neoplasm . | SIg; cIg . | CD5 . | CD10 . | Bcl6 . | CD23 . | CD43 . | CD103 . | Cyclin D1 . | CD 138 . | Genetic Abnormality . | Immunoglobulin Genes* . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: R, rearranged; M, mutated; NK, natural killer cell; U, unmutated; O, ongoing mutations; NA, not available | |||||||||||
| Key: + = >90% positive; +/− = > 50% positive; −/+ = < 50% positive; − = < 10% positive | |||||||||||
| B-SLL/CLL | +; −/+ | + | − | − | + | + | − | − | − | trisomy 12; 13q | R,U (50%); M (50%) |
| Lymphoplasmacytic lymphoma | +; + | − | − | − | − | +/− | − | − | −/+ | t(9;14); del 6(q23) | R,M |
| Hairy cell leukemia | +;− | − | − | − | − | + | ++ | +/− | − | none known | R,M |
| Plasma cell myeloma | −;+ | − | −/+ | − | − | −/+ | − | −/+ | + | t(4:14), t(6;14) t(14;16), t(1;14) | R,M |
| Splenic marginal zone lymphoma | +; −/+ | − | − | − | − | − | + | − | − | none known | R,M |
| Follicular lymphoma | +; − | − | +/− | + | −/+ | − | − | − | − | t(14;18); bcl-2 | R,M,O |
| Mantle cell lymphoma | +; − | + | − | − | − | + | − | + | − | t(11;14); bcl-1 | R,U |
| MALT lymphoma | +; +/− | − | − | − | −/+ | −/+ | − | − | − | +3, t(11;18); API2/MLT1 | R,M,O |
| Diffuse large B-cell lymphoma | +/−; −/+ | − | −/+ | +/− | NA | −/+ | NA | − | −/+ | t(14;18),t(8;14) 3q27; BCL2, cMYC, BCL6 | R,M |
| Burkitt lymphoma | +; − | − | + | + | − | − | NA | − | − | t(8;14), t(2;8), t(8;22); cMYC; EBV−/+ | R,M |
| Neoplasm . | SIg; cIg . | CD5 . | CD10 . | Bcl6 . | CD23 . | CD43 . | CD103 . | Cyclin D1 . | CD 138 . | Genetic Abnormality . | Immunoglobulin Genes* . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: R, rearranged; M, mutated; NK, natural killer cell; U, unmutated; O, ongoing mutations; NA, not available | |||||||||||
| Key: + = >90% positive; +/− = > 50% positive; −/+ = < 50% positive; − = < 10% positive | |||||||||||
| B-SLL/CLL | +; −/+ | + | − | − | + | + | − | − | − | trisomy 12; 13q | R,U (50%); M (50%) |
| Lymphoplasmacytic lymphoma | +; + | − | − | − | − | +/− | − | − | −/+ | t(9;14); del 6(q23) | R,M |
| Hairy cell leukemia | +;− | − | − | − | − | + | ++ | +/− | − | none known | R,M |
| Plasma cell myeloma | −;+ | − | −/+ | − | − | −/+ | − | −/+ | + | t(4:14), t(6;14) t(14;16), t(1;14) | R,M |
| Splenic marginal zone lymphoma | +; −/+ | − | − | − | − | − | + | − | − | none known | R,M |
| Follicular lymphoma | +; − | − | +/− | + | −/+ | − | − | − | − | t(14;18); bcl-2 | R,M,O |
| Mantle cell lymphoma | +; − | + | − | − | − | + | − | + | − | t(11;14); bcl-1 | R,U |
| MALT lymphoma | +; +/− | − | − | − | −/+ | −/+ | − | − | − | +3, t(11;18); API2/MLT1 | R,M,O |
| Diffuse large B-cell lymphoma | +/−; −/+ | − | −/+ | +/− | NA | −/+ | NA | − | −/+ | t(14;18),t(8;14) 3q27; BCL2, cMYC, BCL6 | R,M |
| Burkitt lymphoma | +; − | − | + | + | − | − | NA | − | − | t(8;14), t(2;8), t(8;22); cMYC; EBV−/+ | R,M |